To receive Noxxon’s real time information, please send a request to This email address is being protected from spambots. You need JavaScript enabled to view it.

 

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. NOXXON disavows any obligation to update the information contained in such press releases after the date of their issuance.

Filter: NOX-A12 (olaptesed) | NOX-E36 (emapticap) | all

DateTitleDownload

2022, June 23
08:00 a.m.
NOXXON announces updated development strategy following strong clinical benefit observed with NOX-A12 in combination with radiotherapy and bevacizumab in brain cancer

2022, June 13
08:00 a.m.
NOXXON enters into collaboration with US National Cancer Institute to characterize effects of lead compounds on brain tumors

2022, June 05
03:00 p.m.
NOXXON presents full top-line results from NOX-A12 Phase 1/2 GLORIA trial in glioblastoma at the 2022 ASCO Annual Meeting

2022, June 01
08:00 a.m.
NOXXON to host key opinion leader webinar on GLORIA study top-line results of NOX-A12 and radiotherapy combination in first-line glioblastoma

2022, May 26
11:00 p.m.
NOXXON announces presentation of NOX-A12 Phase 1/2 data in glioblastoma at the 2022 ASCO Annual Meeting and invitation to a dedicated KOL event

2022, April 06
08:00 a.m.
Top-line results from NOXXONs NOX-A12 Phase 1/2 GLORIA trial in brain cancer to be presented during 2022 ASCO Annual Meeting

2022, March 24
08:00 a.m.
NOXXON announces top-line data of Phase 1/2 GLORIA study with NOX-A12 in partially resected or biopsy-only MGMT-unmethylated newly-diagnosed glioblastoma patients

2022, January 07
08:00 a.m.
NOXXON provides progress update on the expansion arms of the Phase 1/2 GLORIA trial with NOX-A12 in brain cancer patients

2022, January 05
07:30 p.m.
NOXXON provides update on evaluation of NOX-A12 in non-oncology indication by a leading international pharma company

2022, January 03
06:00 p.m.
Corrected press release: NOXXON secures €17 million expansion of equity-linked facility with Atlas to advance NOX-A12 in glioblastoma and pancreatic cancer programs

2021, December 29
06:00 p.m.
NOXXON secures Euro 17 million expansion of equity-linked facility with Atlas to advance NOX-A12 in glioblastoma and pancreatic cancer programs

2021, December 07
08:00 a.m.
NOXXON announces enrolment of first patient in the expansion of the NOX-A12 Phase 1/2 trial in brain cancer

2021, December 02
08:00 a.m.
NOXXON summarizes essential points from Key Opinion Leader event on NOX-A12 & radiotherapy combination in brain cancer held on November 23, 2021 with Dr Frank A. Giordano

2021, November 22
08:00 a.m.
NOXXON: New Phase 1/2 data on NOX-A12 & radiotherapy combination in brain cancer presented at the Society for Neuro-Oncology Annual Meeting 2021

2021, November 16
08:00 a.m.
NOXXON to host Key Opinion Leader webinar on NOX-A12 and radiotherapy combination: a differentiated and promising new approach to treating brain cancer

2021, November 12
08:00 a.m.
New positive interim results from NOXXON’s Phase 1/2 GLORIA trial in brain cancer to be presented at the Society for Neuro-Oncology Annual Meeting 2021

2021, November 03
08:00 a.m.
NOXXON provides update on timing for upcoming trials of NOX-A12 in pancreatic and brain cancer

2021, October 19
08:00 a.m.
NOXXON announces planned expansion of Phase 1/2 NOX-A12 brain cancer trial

2021, October 06
08:00 a.m.
NOXXON Pharma announces upcoming oral presentation at the Society for Neuro-Oncology Annual Meeting 2021

2021, September 22
08:00 a.m.
NOXXON enrolls last brain cancer patient in dose escalation portion of GLORIA study and confirms phase 1/2 read-out in Q1 2022

2021, August 05
08:00 a.m.
NOXXON provides update on NOX-A12 clinical programs

2021, July 21
06:00 p.m.
NOXXON Pharma enters second clinical collaboration with MSD to evaluate NOX-A12 in combination with KEYTRUDA (pembrolizumab) in upcoming Phase 2 pancreatic cancer study

2021, June 08
08:00 a.m.
CORRECTED PRESS RELEASE: NOXXON announces positive results from second cohort in Phase 1/2 NOX-A12 brain cancer trial

2021, June 01
06:00 p.m.
NOXXON announces manufacturing of NOX-A12 drug substance for future clinical trials and issuance of convertible bonds under financing agreement with Atlas

2021, June 01
08:00 a.m.
NOXXON announces positive results from second cohort in Phase 1/2 NOX-A12 brain cancer trial

2021, May 10
06:00 p.m.
NOXXON announces Data Safety Monitoring Board validates NOX-A12 highest dose in Phase 1/2 brain cancer trial

2021, April 14
06:00 p.m.
NOXXON successfully completes patient recruitment in Phase 1/2 brain cancer study of NOX-A12 plus radiotherapy

2021, March 12
08:00 a.m.
Data Safety Monitoring Board confirms safety and validates recruitment of last patients in final high-dose cohort of NOX-A12 in Phase 1/2 brain cancer study

2021, February 15
06:00 p.m.
NOXXON enrolls first patient in the high dose cohort of trial combining NOX-A12 with radiotherapy in newly diagnosed brain cancer

2021, February 08
06:00 p.m.
NOXXON appoints leading pancreatic cancer experts to Scientific Advisory Board

2020, December 29
08:00 p.m.
NOXXON announces initiation of NOX-A12 manufacturing for future clinical studies

2020, November 09
08:00 a.m.
NOXXON announces that Data Safety Monitoring Board validates further NOX-A12 dose escalation in Phase 1/2 brain cancer study

2020, October 28
08:00 a.m.
NOXXON announces completion of 6-month therapy for low-dose cohort in Phase 1/2 brain cancer study of NOX-A12 plus radiotherapy

2020, October 20
08:00 a.m.
NOXXON announces three additional clinical centers to recruit patients for NOX-A12 brain cancer trial

2020, October 14
08:00 a.m.
NOXXON announces successful completion of patient recruitment for second dose cohort in phase 1/2 brain cancer study of NOX-A12 plus radiotherapy

2020, September 17
09:00 a.m.
NOXXON presents final clinical data from phase 1/2 NOX-A12 / Keytruda combination trial in colorectal and pancreatic cancer at the ESMO virtual congress 2020

2020, July 24
8:00 a.m.
NOXXON announces first brain cancer patient from second dose cohort reaches 4 weeks of treatment with NOX-A12 combined with radiotherapy

2020, June 30
6:00 p.m.
NOXXON enrolls first patient in the second dose cohort of trial combining NOX-A12 with radiotherapy in newly diagnosed brain cancer

2020, April 27
6:00 p.m.
NOXXON presents latest clinical data from the Phase 1/2 NOX-A12 / Keytruda combination trial in colorectal and pancreatic cancer at the AACR Virtual Annual Meeting 2020

2020, April 24
8:00 a.m.
NOXXON announces that Data Safety Monitoring Board validates NOX-A12 dose escalation in Phase 1/2 brain cancer study

2020, April 14
6:00 p.m.
NOXXON to present latest clinical data from the NOX-A12 / KEYTRUDA combination trial in colorectal and pancreatic cancer at the AACR Virtual Annual Meeting 2020

2020, April 02
8:00 a.m.
NOXXON announces completion of patient recruitment for the first dose cohort in the phase 1/2 brain cancer study of NOX-A12 plus radiotherapy

2019, December 20
8:00 a.m.
NOXXON announces first brain cancer patient reaches 10 weeks of treatment with NOX-A12 plus radiotherapy

2019, October 24
6:00 p.m.
NOXXON publishes interim 2019 results

2019, October 16
8:00 a.m.
NOXXON enrolls first patient in the phase 1/2 clinical trial combining NOX-A12 with radiotherapy in newly diagnosed brain cancer

2019, September 29
12:00 p.m.
NOXXON presents latest clinical data from Phase 1/2 NOX-A12 / Keytruda combination trial at the ESMO congress

2019, September 18
8:00 a.m.
NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the ESMO congress

2019, September 12
6:00 p.m.
NOXXON initiates patient recruitment for phase 1/2 clinical trial combining NOX-A12 & radiotherapy for the treatment of brain cancer patients

2019, June 24
8:00 a.m.
NOXXON announces leading international pharma to evaluate NOX-A12 in new indication

2019, April 01
7:00 p.m.
NOXXON presents updated results from Phase 1/2 NOX-A12 / Keytruda combination trial at AACR 2019

2019, February 28
7:00 p.m.
NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the 2019 AACR Annual Meeting

2019, February 27
6:00 p.m.
NOXXON files application for phase 1/2 clinical trial combining NOX-A12 & radiotherapy for the treatment of brain cancer

2018, December 14
12:30 p.m.
NOXXON announces key findings that NOX-A12 plus Keytruda induces an immune response and results in clinical benefit for patients

2018, December 10
8:00 a.m.
NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at ESMO immuno-oncology congress on December 13-16, 2018

2018, November 21
8:00 a.m.
NOXXON to launch NOX-A12 with radiotherapy clinical trial in patients with brain cancer

2018, October 26
8:00 a.m.
NOXXON to present top-line efficacy data from NOX-A12 / Keytruda combination trial in December as planned at ESMO Immuno-Oncology Conference

2018, October 02
6:00 p.m.
NOXXON presents top-line data from NOX-A12 monotherapy part of ongoing metastatic colorectal and pancreatic cancer trial

2018, September 19
8:00 a.m.
NOXXON to present clinical trial data at Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 'Translating Science into Survival'

2018, September 03
8:00 a.m.
NOXXON announces completion of patient recruitment in ongoing NOX-A12 pancreatic and colorectal cancer trial

2018, June 28
8:00 p.m.
NOXXON provides update on patient recruitment in ongoing NOX-A12 pancreatic and colorectal cancer trial

2018, May 29
8:00 a.m.
NOXXON provides clinical update prior to American Society of Clinical Oncology (ASCO) annual conference

2018, May 15
6:00 p.m.
NOXXON to present clinical trial update at BioEquity Europe

2017, October 03NOXXON Publishes Preclinical Proof-Of-Concept Data for Lead Compound NOX-A12 in Combination with Checkpoint Inhibitors

2017, September 28NOXXON provides update on ongoing phase 1/2 clinical trial with lead program NOX-A12

2017, July 04NOXXON announces first patients treated in phase I/II clinical trial of NOX-A12 combined with Keytruda in metastatic pancreatic and colorectal cancer

2017, May 16NOXXON Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12/Keytruda phase 1/2 combination trial

2016, December 15NOXXON Pharma signs clinical immuno-oncology collaboration agreement with MSD to study NOX-A12 combined with Keytruda (pembrolizumab) in pancreatic and colorectal cancer

2016, December 05NOXXON Pharma announces new preclinical data showing synergy of lead compound NOX-A12 with natural killer (NK) Cell mediated therapies

2016, October 10NOXXON Pharma demonstrates synergies between NOX-A12 and therapies working through T cells or NK cells

2014, December 05Phase IIa Results for Spiegelmer Olaptesed Pegol (NOX-A12) in MM and CLL at 2014 American Society of Hematology (ASH) Conference

2014, September 26Cell Reports Publication on the Mechanism of Action of NOXXONs Anti-SDF-1 Spiegelmer Olaptesed Pegol (NOX-A12) in Preclinical Multiple Myeloma Models

2014, September 23NOXXON Spiegelmer receives FDA Orphan Drug Designation for Glioblastoma Treatment

2014, June 13NOXXON presents Updates on Phase II Studies with Olaptesed Pegol (NOX-A12) in CLL and MM and Lexaptepid Pegol (NOX H94) in Anemic Cancer Patients

2013, December 09NOXXON presenting at ASH 2013

2012, September 26NOXXON Initiates Phase IIa Trial of anti-CXCL12/SDF-1 Spiegelmer NOX-A12 in Second Oncology Indication: Multiple Myeloma

2012, July 11NOXXON Initiates Phase IIa of anti-CXCL12/SDF-1 Spiegelmer NOX-A12 for Treatment of Chronic Lymphocytic Leukemia

2012, April 4NOXXONs NOX-A12 Delays Glioblastoma Recurrence in Preclinical Model

2011, December 12NOXXONs SDF-1 inhibitor NOX-A12 completes Phase I

2010, September 22NOXXON initiates multiple dose phase I clinical trial of SDF-1 inhibitor NOX-A12

2010, May 3NOXXON Announces the Completion of the First-in-Human Clinical Trial with Spiegelmer NOX-A 12

2009, November 2NOXXON Announces Initiation of First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer NOX-A12

2009, September 3NOXXON Is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer NOX-A12